A total of eight patents on four items were listed on the medical patent list in October.
According to the Ministry of Food and Drug Safety, Gilead Sciences and Pfizer acquired domestic patents last month.
Gilead has registered three patents (a total of six) on the two ‘remdesivir’ ingredient drugs (veklury concentrate for solution for infusion, veklury powder for concentrate for solution for infusion). Remdesivir has attracted public attention as a treatment for coronavirus infection.
These two products differ in their properties, but they both can be used on patients with coronavirus confirmed through PCR test (a test method that amplifies target nucleic acids).
Also, at least one of these should be applied to the patients ▲with 94% or less SpO2 in room air ▲requiring supplemental oxygen therapy ▲requiring non-invasive or invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO), and they were approved in Korea on July 24th.
Pfizer has won two domestic patents on a targeted anticancer drug of PARP inhibition mechanism, one each for two items, Talzenna Cap. (0.25mg, 1mg, talazoparib tosylate) on July 30th.
They have been administered as monotherapy on patients with a gBRCA and HER2-negative locally advanced or metastatic breast cancer who previously had chemotherapy experience.
